These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16685247)

  • 1. Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar).
    Med Lett Drugs Ther; 2006 May; 48(1234):39-40. PubMed ID: 16685247
    [No Abstract]   [Full Text] [Related]  

  • 2. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
    Campbell JM; Stephenson MD; Bateman E; Peters MD; Keefe DM; Bowen JM
    Pharmacogenomics J; 2017 Jan; 17(1):21-28. PubMed ID: 27503581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
    Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
    Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
    Peng H; Duan Z; Pan D; Wen J; Wei X
    Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
    Biason P; Masier S; Toffoli G
    J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics and irinotecan therapy.
    Hahn KK; Wolff JJ; Kolesar JM
    Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
    Ichikawa W; Araki K; Fujita K; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Kodama K; Sunakawa Y; Narabayashi M; Ando Y; Akiyama Y; Kawara K; Sasaki Y
    J Natl Cancer Inst; 2008 Feb; 100(3):224-5; author reply 225. PubMed ID: 18230796
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
    Innocenti F; Ratain MJ
    Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
    Yan L; Wang XF; Wei LM; Nie YL; Liu JY; Zhang LR
    Int J Clin Pharmacol Ther; 2016 Mar; 54(3):193-9. PubMed ID: 26857783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
    Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
    Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan pharmacogenetics: is it time to intervene?
    McLeod HL; Watters JW
    J Clin Oncol; 2004 Apr; 22(8):1356-9. PubMed ID: 15007084
    [No Abstract]   [Full Text] [Related]  

  • 13. The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis.
    Chen YJ; Hu F; Li CY; Fang JM; Chu L; Zhang X; Xu Q
    Biomarkers; 2014 Feb; 19(1):56-62. PubMed ID: 24308720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
    Fakih MG; Ross ME; Starostik P
    Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pharmacogenetic factors associated with irinotecan toxicity.
    Kweekel D; Guchelaar HJ; Gelderblom H
    Cancer Treat Rev; 2008 Nov; 34(7):656-69. PubMed ID: 18558463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
    Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
    Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
    Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; Ramírez J; Rudin CM; Vokes EE; Ratain MJ
    J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
    Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
    Takano M; Kato M; Yoshikawa T; Goto T; Furuya K; Kikuchi Y
    Int J Clin Oncol; 2010 Apr; 15(2):224-5. PubMed ID: 20179984
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
    Mehra R; Murren J; Chung G; Smith B; Psyrri A
    Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.